Paclitaxel-albumin-binding agent compositions and methods for using and making the same
View Patent ↗Described herein are nanoparticle compositions comprising binding agents, carrier proteins and an amount of paclitaxel derivative, and optionally a therapeutic agent. Also described herein are nanoparticle compositions comprising carrier proteins and an amount of paclitaxel, and optionally binding agents and/or a therapeutic agent, wherein the paclitaxel is present in an amount that is less than an amount that provides a therapeutic effect. Also disclosed herein are nanoparticles which contain (a) carrier protein, (b) a paclitaxel derivative, the paclitaxel derivative having reduced toxicity compared to paclitaxel, and optionally (c) a binding agent and/or (d) a therapeutic agent. Also described are methods of making and using the same, in particular, as a cancer therapeutic.
1. A nanoparticle complex comprising albumin, 20-acetoxy-4-deacetyl-5-epi-20,O-secotaxol, and antibodies having an antigen-binding domain, wherein the antibodies are bound to the albumin through non-covalent bonds and are arranged on an outside surface of the nanoparticle complexes and wherein the 20-acetoxy-4-deacetyl-5-epi-20,O-secotaxol is less toxic than paclitaxel.
2. The nanoparticle complex of claim 1 , further comprising a therapeutic agent.
3. The nanoparticle complex of claim 2 , wherein the therapeutic agent is selected from abiraterone, bendamustine, bortezomib, carboplatin, cabazitaxel, cisplatin, chlorambucil, dasatinib, docetaxel, doxorubicin, epirubicin, erlotinib, etoposide, everolimus, gefitinib, idarubicin, hydroxyurea, imatinib, lapatinib, leuprorelin, melphalan, methotrexate, mitoxantrone, nedaplatin, nilotinib, paclitaxel, pazopanib, pemetrexed, picoplatin, romidepsin, satraplatin, sorafenib, vemurafenib, sunitinib, teniposide, triplatin, vinblastine, vinorelbine, vincristine, or cyclophosphamide.
4. The nanoparticle complex of claim 1 , wherein the albumin and the paclitaxel derivative have a relative weight ratio of less than about 10:1.
5. The nanoparticle complex of claim 1 , wherein the antigen is CD3, CD 19, CD20, CD38, CD30, CD33, CD52, PD-1, PD-L1, PD-L2, CTLA-4, RANK-L, GD-2, Ly6E, HER3, EGFR, DAF, ERBB-3 receptor, CSF-IR, HER2, STEAP1, CD3, CEA, CD40, OX40, Ang2-VEGF, or VEGF.
6. The nanoparticle complex of claim 1 which is lyophilized.
7. The nanoparticle complex of claim 6 which is stable at about 20° C. to about 25° C. for up to about 12 months or longer.
8. The nanoparticle complex of claim 1 , which is not oligomerized.
9. The nanoparticle complex of claim 1 having a size between about 70 nm and about 800 nm.
10. The nanoparticle complex of claim 1 having a size between about 100 nm and about 200 nm.
11. The nanoparticle complex of claim 1 , wherein the antibodies are selected from alemtuzumab, atezolizumab, bevacizumab, cetuximab, denosumab, dinutuximab, ipilimumab, nivolumab, obinutuzumab, ofatumumab, panitumumab, pembrolizumab, pertuzumab, rituximab, avelumab, durvalumab, pidilizumab, BMS 936559, OKT3, and trastuzumab.
12. The nanoparticle complex of claim 1 , wherein the albumin is human serum albumin.
13. The nanoparticle complex of claim 12 , wherein the albumin is recombinant human serum albumin.
14. The nanoparticle complex of claim 1 having a dissociation constant between about 1×10 −11 M and about 1×10 −9 M.
15. A composition comprising the nanoparticle of claim 1 .
16. A method for killing cancer cells in a population of cancer cells, the method comprising contacting the cells with an effective amount of the nanoparticle of claim 1 , wherein said nanoparticle is maintained in contact with said cells for a sufficient period of time to kill cancer cells.
17. A method for treating cancer in patient in need thereof, the method comprising administering to the patient the composition of claim 15 .